Journal article

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Achim A Jungbluth, Elisabeth Stockert, HJ Su Huang, Vincent P Collins, Keren Coplan, Kristin Iversen, Denise Kolb, Terrance J Johns, Andrew M Scott, William J Gullick, Gerd Ritter, Leonard Cohen, Matthew J Scanlan, Webster K Cavenee, Lloyd J Old

Proceedings of the National Academy of Sciences of the United States of America | Published : 2003

Abstract

Epidermal growth factor receptor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type (wt)EGFR is amplified/overexpressed in a number of tumor types, and several mutant forms of the coding gene have been found, with DeltaEGFR, a deletion mutation lacking exons 2-7 of the external domain, being the most common and particularly associated with glioblastoma. We generated monoclonal antibodies (mAbs) against NR6(DeltaEGFR) (mouse fibroblast line NR6 transfected with DeltaEGFR). mAb 806 with selective reactivity for NR6(DeltaEGFR) in mixed hemadsorption assays, fluorescence-activated cell sorting, Western blot, and immunohistochemistry was analyzed in detail and c..

View full abstract

University of Melbourne Researchers